Advanced search
Publication Cover
Journal of Chemotherapy Volume 19, 2007 - Issue 3
Submit an article Journal homepage
47
Views
17
CrossRef citations to date
0
Altmetric
Anticancer Chemotherapy

The Efficacy of Rituximab plus Hyper-CVAD Regimen in Mantle Cell Lymphoma Is Independent of FCγRIIIa and FCγRIIa Polymorphisms

S. Galimberti
,
G.A. Palumbo
,
F. Caracciolo
,
E. Benedetti
,
M. Pelosini
,
S. Brizzi
,
E. Ciabatti
,
R. Fazzi
,
C. Stelitano
,
G. Quintana
,
E. Conte
,
D. Tibullo
,
F. Di Raimondo
&
M. Petrini
 show all
Pages 315-321 | Published online: 18 Jul 2013

Citations (17)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Sara Galimberti, Balint Nagy, Eugenio Ciancia, Francesco Caracciolo, Edoardo Benedetti, Matteo Pelosini, Daniele Focosi & Mario Petrini. (2011) Outcome of patients with mantle cell lymphoma is not influenced by vascular endothelial growth factor polymorphisms. Leukemia & Lymphoma 52:1, pages 142-144.
Read now
Samuel A Jacobs & Kenneth A Foon. (2007) The expanding role of rituximab and radioimmunotherapy in the treatment of B-cell lymphomas. Expert Opinion on Biological Therapy 7:11, pages 1749-1762.
Read now

Articles from other publishers (15)

Anne Bordron, Marie Morel & Cristina Bagacean. 2024. Resistance to Anti-Cd20 Antibodies and Approaches for their Reversal. Resistance to Anti-Cd20 Antibodies and Approaches for their Reversal 231 247 .
Ming Sun & Han Zhang. (2019) Therapeutic antibodies for mantle cell lymphoma: A brand-new era ahead. Heliyon 5:3, pages e01297.
Crossref
Matthew J. Barth & Stanton C. Goldman. 2019. Resistance to Targeted Therapies in Lymphomas. Resistance to Targeted Therapies in Lymphomas 27 55 .
Birgit Burkhardt, Deniz Yavuz, Martin Zimmermann, Jutta Schieferstein, Edita Kabickova, Andishe Attarbaschi, Jasmin Lisfeld, Alfred Reiter, Olga Makarova, Jennifer Worch, Bettina R. Bonn & Christine Damm-Welk. (2016) Impact of Fc gamma-receptor polymorphisms on the response to rituximab treatment in children and adolescents with mature B cell lymphoma/leukemia. Annals of Hematology 95:9, pages 1503-1512.
Crossref
Duo Liu, Yuyang Tian, Donglin Sun, Haiming Sun, Yan Jin & Mei Dong. (2016) The FCGR3A polymorphism predicts the response to rituximab-based therapy in patients with non-Hodgkin lymphoma: a meta-analysis. Annals of Hematology 95:9, pages 1483-1490.
Crossref
D. Pérez-Callejo, J. González-Rincón, A. Sánchez, M. Provencio & M. Sánchez-Beato. (2015) Action and resistance of monoclonal CD20 antibodies therapy in B-cell Non-Hodgkin Lymphomas. Cancer Treatment Reviews 41:8, pages 680-689.
Crossref
Andrew R. Rezvani & David G. Maloney. (2011) Rituximab resistance. Best Practice & Research Clinical Haematology 24:2, pages 203-216.
Crossref
Robert A. Baiocchi, Lapo Alinari, Mark E. Lustberg, Thomas S. Lin, Pierluigi Porcu, Xiaobai Li, Jeffrey S. Johnston, John C. Byrd & Kristie A. Blum. (2010) Phase 2 trial of rituximab and bortezomib in patients with relapsed or refractory mantle cell and follicular lymphoma. Cancer 117:11, pages 2442-2451.
Crossref
David DornanOlivia SpleissRu-Fang YehGuillemette Duchateau-NguyenAnnika DufourJianguo ZhiTadeusz RobakSergey I. MoiseevAnna DmoszynskaPhilippe Solal-CelignyKrzysztof WarzochaJavier LoscertalesJohn CatalanoBoris V. AfanasievLoree LarrattViktor A. RossievIsabelle Bence-BrucklerChristian H. GeislerMarco MontilloMichael K. Wenger & Martin Weisser. (2010) Effect of FCGR2A and FCGR3A variants on CLL outcome. Blood 116:20, pages 4212-4222.
Crossref
Yun Zhuang, Wei Xu, Yunfeng Shen & Jianyong Li. (2010) Fcγ Receptor Polymorphisms and Clinical Efficacy of Rituximab in Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia. Clinical Lymphoma Myeloma and Leukemia 10:5, pages 347-352.
Crossref
Wasif Riaz, Francisco J. Hernandez-Ilizaliturri & Myron S. Czuczman. (2009) Strategies to enhance rituximab anti-tumor activity in the treatment of CD20-positive B-cell neoplasms. Immunologic Research 46:1-3, pages 192-205.
Crossref
Kenneth A. Foon, Michael Boyiadzis & Samuel A. Jacobs. 2010. Macromolecular Anticancer Therapeutics. Macromolecular Anticancer Therapeutics 493 536 .
Daniel L. Hertz, Howard L. McLeod & Janelle M. Hoskins. (2009) Pharmacogenetics of breast cancer therapies. The Breast 18, pages S59-S63.
Crossref
Ross Stewart & Carl Webster. 2009. Recombinant Antibodies for Immunotherapy. Recombinant Antibodies for Immunotherapy 111 123 .
Rogier M. Thurlings, Koen Vos, Daniëlle M. Gerlag & Paul P. Tak. (2008) Disease activity-guided rituximab therapy in rheumatoid arthritis: The effects of re-treatment in initial nonresponders versus initial responders. Arthritis & Rheumatism 58:12, pages 3657-3664.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.